Detail akcie Amphastar Pharmactc online

Business Summary: Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Amphastar Pharmaceuticals, Inc revenues increased less than 1% to $171.2M. Net income decreased 75% to $6.4M. Revenues reflect China segment increase from $81K to $2.5M, France segment increase of 23% to $9.6M, also reflect United States segment decrease of 2% to $159M. Net income was partially offset by Research and development increase of 43% to $11.2M (expense).